SMC issues positive advice for first ever treatment for ADPKD

JINARC® (tolvaptan) is accepted for use in Scotland for the treatment of autosomal dominant polycystic kidney disease (ADPKD)

Source: Pharmacy Europe - January 11, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Legislation & regulation Nephrology Patient care adpkd jinarc Latest News smc tolvaptan Source Type: news